Cancer Network
Spotlight
CancerNetwork® Inaugural Face-OffContemporary Concepts in Hematologic OncologyReal-World Evidence in NSCLC Guides Clinical Decisions Register: Recent Advances in Multiple Myeloma: Insights from Experts at Dana Farber Cancer Institute and Massachusetts General Hospital
Clinical
View MoreAcute Myeloid LeukemiaBrain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
News
Clinical TopicsIntegrative CareGlobal BulletinAll NewsApproval Alert
Media
2 Minute DrillAround the PracticeBetween the LinesClinical ConsultExpert InterviewsFace OffMedical World NewsOncViewPodcastsReadout 360Year in Review
Conferences
Publications
All JournalsFor AuthorsTumor Board
CME/CE
Resources
Contemporary ConceptsInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Subscribe
eNewsletterPrint Subscription

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences and Cancer Network. All rights reserved.

Spotlight
  • CancerNetwork® Inaugural Face-Off
  • Contemporary Concepts in Hematologic Oncology
  • Real-World Evidence in NSCLC Guides Clinical Decisions
  • Register: Recent Advances in Multiple Myeloma: Insights from Experts at Dana Farber Cancer Institute and Massachusetts General Hospital
ClinicalSee All >
  • Acute Myeloid Leukemia
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecologic Cancer
  • Hematology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Pediatric Cancers
  • Skin Cancer
  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.

Geriatric consultations vs standard of care for patients with hematologic malignancies who were pre-frail or frail did not significantly improve survival at 1 year but did increase discussions on end-of-life goals of care.

View Article

Elderly patients with multiple myeloma who were treated with first-line bortezomib had a higher risk of falls vs age-matched controls.

View Article

A phase 2 trial shows promise of the daratumumab/ixazomib combination in frail and elderly patients with multiple myeloma who are treated in the relapsed setting when given without dexamethasone.

View Article

Older patients undergoing treatment for B-cell malignancies who contracted the COVID-19 virus were at an increased risk of death vs patients with other cancers under the age of 60 years.

View Article

The phase 2 HORIZON study indicated that melflufen plus dexamethasone (Ozurdex) demonstrated clinically meaningful efficacy as well as a manageable safety profile in patients with heavily pretreated relapsed/refractory multiple myeloma.

View Article